International Conference on Viral Hepatitis 2013
The International Conference on Viral Hepatitis 2013 was jointly sponsored by the Icahn School of Medicine at Mount Sinai and the International Association of Providers of AIDS Care (IAPAC). The conference was co-chaired by Douglas T. Dieterich, MD (Icahn School of Medicine at Mount Sinai, New York, NY, USA) and Mark R. Nelson, MD (Chelsea & Westminster Hospital, London, England).
Following are conference presentations. The conference organizers request that any use of these presentations should include citations to both their presenting authors and relevant conference information (e.g., International Conference on Viral Hepatitis 2013, March 25-26, 2013, New York).
MONDAY, March 25, 2013
PLENARY 1 – A Global Snapshot of Viral Hepatitis Morbidity and Mortality
John Ward, MD, US Centers for Disease Control and Prevention, Atlanta, GA, USA
PLENARY 2 – Viral Hepatitis in Low- and Middle-Income Countries: Narrowing the Gap
Graham S. Cooke, MD, PhD, Imperial College, London, ENGLAND
PLENARY 3 – HBV Management – An Overview Spanning Monoinfection and Complex Coinfections
Douglas T. Dieterich, MD, Icahn School of Medicine at Mount Sinai, New York, NY, USA
PLENARY 4 – HCV Management – After the Hype Addressing the Realities of the DAA Era
Massimo Puoti, MD, AO Ospedale Nigaurda Cà Granda, Milan, ITALY
KEYNOTE ADDRESS – Genetics/Genomics in Hepatitis and Liver Disease
Scott. L Friedman, MD, Icahn School of Medicine at Mount Sinai, New York, NY, USA
PANEL DISCUSSION 1 – The HCV Pipeline: Perspectives from the Bench with Implications for the Clinic
Moderator: Douglas T. Dieterich, MD, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Panelist 1: Barbara McGovern, MD, AbbVie, North Chicago, IL, USA
Panelist 2: Stephanie Noviello, MD, MPH, Bristol-Myers Squibb, Princeton, NJ, USA
Panelist 3: William A. O’Brien, MD, MS, Boehringer Ingelheim, Ridgefield, CT, USA
PLENARY 5 – Acute HCV Infection – Experiences from Europe and the United States
Panelist 1: Emma Page, MD, Chelsea & Westminster Hospital, London, ENGLAND Presentation
Panelist 2: Daniel S. Fierer, MD, Icahn School of Medicine at Mount Sinai, New York, NY, USA Presentation
PLENARY 6 – Chronic HCV Infection – Experiences from Europe and the United States
Panelist 1: Massimo Puoti, MD, AO Ospedale Nigaurda Cagrave; Granda, Milan, ITALY Presentation
Panelist 2: Valérie Martel-Laferrière, MD, Icahn School of Medicine at Mount Sinai, New York, NY, USA Presentation
TUESDAY, March 26, 2013
PLENARY 7 – HIV and the Liver: Hepatoxicity of Antiretroviral Therapy and Other Clinical Management Concerns
Martin Fisher, MBBS, Royal Sussex County Hospital, Brighton, ENGLAND
PLENARY 8 – Pharmacodynamics and Drug-Drug Interactions in HCV/HIV-Coinfected Patients on HCV Treatment with DAAs
Courtney Fletcher, PharmD, University of Nebraska Medical Center, Omaha, NE, USA
PLENARY 9 – Managing HCV in Cirrhotic Patients Pre- and Post-Liver Transplant
K. Rajender Reddy, MD, University of Pennsylvania, Philadelphia, Philadelphia, PA, USA
DEBATE SESSION 1 – Reopening the Liver Transplant and HIV Debate: The Pros, The Cons, and The Gray Areas
Moderator: Massimo Puoti, MD, AO Ospedale Nigaurda Cagrave; Granda, Milan, ITALY
Panelist 1: Peter Stock, MD, University of California, San Francisco, San Francisco, CA, USA Presentation
Panelist 2: Kosh Agarwal, MD, King’s College Hospital, London, ENGLAND Presentation
PANEL DISCUSSION 2 – Managing Adverse Events in the HIV/HCV-Coinfected Patient in the Era of DAA-Based ART
Moderator: Jeffrey Kwong, DNP, MPH, ANP-BC, Rutgers, The State University of New Jersey, Newark, NJ, USA
Panelist 1: Jacob Langness, PharmD, University of Colorado Hospital, Aurora, CO, USA
Panelist 2: Monique J. Carasso, MSN, ANP-C, Weill Cornell Medical College, New York, NY, USA
Panelist 3: Sherilyn Brinkley, CRNP, Johns Hopkins University, Baltimore, MD, USA
PANEL DISCUSSION 3 – Perspectives on What Providers Need to Know About Stigma and Other Barriers to Hepatitis Care
Moderator: Jeffrey Weiss, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Panelist 1: Alyson Harty
Panelist 2: Enrique Menendez
Panelist 3: Andrew Styles
Panelist 4: José Bisono
CASE STUDY PANEL DISCUSSION – Complicated Acute and Chronic Hepatitis Cases
Moderator 1: Douglas T. Dieterich, MD, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Moderator 2: Mark R. Nelson, MD, Chelsea & Westminster Hospital, London, ENGLAND
Panelist 1: Daniel S. Fierer, MD, Icahn School of Medicine at Mount Sinai, New York, NY, USA Presentation
Panelist 2: Massimo Puoti, MD, AO Ospedale Nigaurda Cà Granda, Milan, ITALY Presentation
Panelist 3: Martin Fisher, MBBS, Royal Sussex County Hospital, Brighton, ENGLAND Presentation
PANEL DISCUSSION 4 – Improving Liver Disease Outcomes: New Drugs, New Strategies, New Realities
Moderator: Jeffrey Weiss, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Moderator 1: Douglas T. Dieterich, MD, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Moderator 2: Mark R. Nelson, MD, Chelsea & Westminster Hospital, London, ENGLAND
Panelist 1: Jeffrey Weiss, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, USA Presentation
Panelist 2: Vincent Soriano, MD, PhD, Hospital Carlos III, Madrid, SPAIN Presentation
Panelist 3: Monique J. Carasso, MSN, ANP-C, Weill Cornell Medical College, New York, NY, USA Presentation
Panelist 4: Kosh Agarwal, MD, King’s College Hospital, London, ENGLAND Presentation
ORAL ABSTRACT PRESENTATIONS
6 – HCV and HBV Testing Acceptability and Knowledge among Urban Emergency Department Patients and Pharmacy Clients
Mark Iscoe presenting
8 – Longitudinal Changes in Liver Fibrosis According to Response to Chronic Hepatitis C Therapy in HCV/HIV-Coinfected Patients
Pablo Labarga presenting
10 – Changes in Circulating HCV-RNA Concentrations in Patients with Chronic Hepatitis C in the Absence of Antiviral Therapy
Vincent Soriano presenting
12 – Scaling up Epidemics of Acute Hepatitis C and Syphilis in HIV-Infected Men who Have Sex with Men in Spain
Vincent Soriano presenting
14 – Interferon-Free Combination Treatment with the HCV NS3/4A Protease Inhibitor BI201335 (faldaprevir) and the Nonnucleoside NS5B Inhibitor BI207127 ± Ribavirin (R): Final Results of SOUND-C2 and Predictors of Response
Federico Mensa presenting
15 – Quality of HCV Testing and Treatment and Counseling in New York State
Leah Savitsky presenting
18 – Results of Community-Based Rapid HCV Testing in New York City
Korin Parrella presenting
24 – Clinical Experience of Boceprevir for the Treatment of Chronic Hepatitis C in HIV Coinfection
Alison Boyle presenting on behalf of Amena Ahmed
25 – Characterization of Resistance-Associated Variants Selected in GT1, GT2, and GT3 Replicons by the HCV Protease Inhibitor MK5172
Robert Chase presenting/p>
28 – TA Combination Containing MK-5172 (HCV NS3 protease inhibitor) and MK-8742 (HCV NS5A inhibitor) Demonstrates High Barrier to Resistance in HCV Replicons
Frederick C. Lahser presenting
31 – On-Treatment Responses to Telaprevir-based Hepatitis C Treatment Are Similar in HIV/HCV Coinfected and HCV Monoinfected Patients
Valérie Martel-Laferrière presenting
46 – EMR Upgrade for HCV Screening and Treatment
Andrew Hamilton presenting
<!–
Click here to receive an email notice regarding next year’s International Conference on Viral Hepatitis.
–>
2013 Conference Program and Abstracts
Click below to download the complete 2013 Program in PDF format.
Requires free Acrobat Reader Plugin Software
